STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2019

Sep 20, 2019

September 20, 2019

BSE Limited

BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza , Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR

Dear Sirs,

Sub: Strides Press Release dated September 20, 2019 titled ‘Strides Board approves incremental investments in Stelis’

With reference to above, please also find enclosed the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the said transaction.

Thanks and Regards,

For Strides Pharma Science Limited

==> picture [132 x 58] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [96 x 86] intentionally omitted <==

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Incremental Investment in Stelis Biopharma Private Limited

Sr. No	Particulars	Remarks
1.	Name of the Target entity, details in brief such as size, turnover etc.	Stelis Biopharma Private Limited (Stelis). The Company is in investment phase and has not started commercial operations
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	Yes – Strides already holds around ~43% in Stelis and Stelis is an Associate Company of Strides.
3.	Industry to which Target entity being acquired belongs	Biopharma
4.	Objects and effects of acquisition	The proposed new investments will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides’ re-entry into sterile injectables business.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None
6.	Indicative time period for completion	Investment to be made over a period of 24 months
7.	Nature of consideration	Cash
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	Strides to have a controlling stake in Stelis

Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942info@strides.com; www.strides.com

9.	Cost of acquisition or the price at which the shares are acquired	Investment up to a maximum of ~US$ 40 million
10.
a.	Products/ line of business acquired	Biopharma
b.	Date of incorporation	12-June-2007
c.	History of last 3 years turnover	The Company is in investment phase and has not started commercial operations
d.	Country in which the acquired entity has presence	India
e.	Any other significant information	-

Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942info@strides.com; www.strides.com